Compare PI & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PI | PCVX |
|---|---|---|
| Founded | 2000 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 7.0B |
| IPO Year | 2011 | 2020 |
| Metric | PI | PCVX |
|---|---|---|
| Price | $143.46 | $55.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | ★ $206.44 | $116.40 |
| AVG Volume (30 Days) | 297.0K | ★ 1.5M |
| Earning Date | 10-28-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $122,633,000.00 | N/A |
| Revenue This Year | $10.27 | N/A |
| Revenue Next Year | $19.25 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $87.96 | $42.40 |
| 52 Week High | $215.25 | $90.75 |
| Indicator | PI | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 29.87 | 37.04 |
| Support Level | $127.05 | $53.43 |
| Resistance Level | $151.68 | $62.44 |
| Average True Range (ATR) | 9.58 | 3.10 |
| MACD | -2.64 | -0.97 |
| Stochastic Oscillator | 3.24 | 1.61 |
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.